Gliomas are aggressive brain tumors with poor prognosis, and new therapeutic strategies are urgently needed. This study used a combined in silico (computer modeling) and in vitro (laboratory cell) approach to evaluate whether compounds from Cannabis sativa—including cannabichromene (CBC) and cannabigerol (CBG)—as well as related natural molecules, may inhibit the growth of malignant glioma cells. The research examined how these compounds interact with molecular targets linked to cancer progression and then tested their effects on glioma cell survival in the lab.

Initial computer simulations suggested that CBC, CBG, and certain related compounds could bind to targets involved in glioma cell proliferation and survival. When tested in cultured glioma cells, several of the cannabinoids significantly reduced tumor cell viability compared with untreated controls. The results indicated that these compounds may interfere with signaling pathways important for cancer cell growth and survival. While CBC and CBG demonstrated the most notable activity, other related molecules also showed varying degrees of antitumor effects.

Although this research is in early stages and was conducted outside of living organisms, the findings highlight potential antitumor properties of specific cannabinoid compounds against aggressive brain tumor cells. The authors emphasize that further research—including animal studies and clinical trials in humans—is needed to confirm safety, effective dosing, and whether these effects translate into meaningful therapeutic benefits.

Source

Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds from Cannabis sativa and Piper nigrum Against Malignant Glioma: An In Silico to In Vitro Approach (June 2025)
Available through the National Library of Medicine (NIH): https://pmc.ncbi.nlm.nih.gov/articles/PMC12192948/